Evgenii A. Osmanov

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

Tadeusz Robak, Huiqiang Huang, Jie Jin et al. · New England Journal of Medicine · 2015 · 375 citations · Full text

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Fritz Offner, Olga Samoilova, Evgenii A. Osmanov et al. · Blood · 2015 · 135 citations · Full text

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong et al. · The Lancet Oncology · 2011 · 108 citations

Hematological Malignancy, Lymphoid Neoplasia, Rituximab Versus Rituximab +6

Multiple myeloma

Evgenii A. Osmanov, I V Poddubnaya, Aleksei A. Nevol’skikh et al. · Journal of Modern Oncology · 2021 · 27 citations · Full text